Docetaxel liposomal - Innomedica
Alternative Names: Liposomal docetaxel - Innomedica; TLTX-1Latest Information Update: 10 Sep 2024
At a glance
- Originator InnoMedica
- Class Antineoplastics; Small molecules; Taxanes
- Mechanism of Action Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation promoters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 10 Sep 2024 Docetaxel liposomal is still in preclinical trials for cancer in Switzerland (Innomedica pipeline, September 2024)
- 28 May 2024 No recent reports of development identified for preclinical development in Cancer in Switzerland (Parenteral)